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Abstract
Background: During the 2012 cholera outbreak in the Republic of Guinea, the Ministry of Health, supported by Me´decins
Sans Frontie`res - Operational Center Geneva, used the oral cholera vaccine Shanchol as a part of the emergency response.
The rapid diagnostic test (RDT) Crystal VC, widely used during outbreaks, detects lipopolysaccharide antigens of Vibrio
cholerae O1 and O139, both included in Shanchol. In the context of reactive use of a whole-cell cholera vaccine in a region
where cholera cases have been reported, it is essential to know what proportion of vaccinated individuals would be reactive
to the RDT and for how long after vaccination.
Methodology/Principal Findings: A total of 108 vaccinated individuals, selected systematically among all persons older
than one year, were included at vaccination sites and 106 were included in the analysis. Stools samples of this cohort of
vaccinated participants were collected and tested with the RDT every day until the test was negative for two consecutive
visits or for a maximum of 7 days. A total of 94.3% of cholera vaccine recipients had a positive test after vaccination; all
except one of these positive results were reactive only with the O139 antigen. The mean time to become negative in those
with an initial positive result after vaccination was 3.8 days, standard deviation 1.1 days.
Conclusions/Significance: The RDT Crystal VC becomes positive in persons recently vaccinated against cholera, although
almost exclusively to the O139 antigen. This reactivity largely disappeared within five days after vaccination. These results
suggest that the test can be used normally as soon as 24 hours after vaccination in a context of O1 epidemics, which
represent the vast majority of cases, and after a period of five days in areas where V. cholerae O139 is present. The reason
why only O139 test line became positive remains to be investigated.
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Introduction
Cholera is an acute diarrhoeal infection caused by ingestion of
the bacterium Vibrio cholerae. Two serogroups– O1 and O139 – are
responsible for cholera epidemics. While V. cholerae O1 causes the
majority of outbreaks over the world, O139 – first identified in
Bangladesh in 1992 – is confined to South-East Asia [1], where its
incidence has declined over the years [2]. Globally, O139 accounts
for a small minority of cholera cases [3], and local transmission has
never been reported in Africa or America. Rapid identification of
initial cases of cholera in the early phase of an epidemic is critical
for implementation of a timely public health response [4] to
control the spread and duration of the outbreak. Currently,
cholera diagnosis relies on the microbiological identification of the
pathogen by stool culture, which remains the gold standard to
confirm the diagnosis [5]. However, this procedure requires
laboratory infrastructure, adequate transport procedures and
trained staff [5]. As rapid diagnostic tests (RDT) require less time,
a minimum laboratory infrastructure and basic technical skills,
they are used to confirm cholera outbreaks in places where high
laboratory standards are difficult to obtain [6].
In 2003, the Institut Pasteur developed a cholera RDT based on
the qualitative detection of lipopolysaccharide (LPS) antigen of
both Vibrio cholerae O1 and O139 serogroups from stool specimens.
This test uses one-step, vertical-flow immunochromatography
principle and monoclonal antibodies against the core and O-
specific polysaccharides of each serogroup for capture and
detection of antigens [7,8]. The O1 specific antigenic determinant
is common to Ogawa and Inaba serotypes [8,9] and the one for
O139 is common to both O139 capsular polysaccharide and LPS.
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This cross-reactivity between O139 LPS and capsular polysac-
charide explains that antibodies react with both encapsulated and
non-encapsulated V. cholerae O139 strains [10]. The RDT is
produced by Span Diagnostics (Surat, India) under the trade name
Crystal VC [5]. Several evaluations have shown good sensitivity,
ranging from 92% to 100% [7,11–12]. In contrast, the specificity
was lower and most evaluations in field conditions have shown
specificities from 71% to 77% when compared with culture as the
gold standard [4,11–13]. Nevertheless, the use of culture as gold
standard may underestimate specificity, and re-analysis of the data
using statistical methods for evaluation with an imperfect gold
standard showed that the specificity could be around 85% [14].
After these evaluations, the manufacturer SPAN changed the test
presentation (order of the lines and addition of a dilution buffer),
but the test in this new version has not been formally evaluated.
This test is widely used for epidemiological purposes during
outbreaks.
In 2012, the Republic of Guinea faced an O1 cholera epidemic,
with the first cases notified in the prefecture of Fore´cariah in
February. In light of the ongoing cholera epidemic and the 2009
World Health Organization (WHO) recommendations calling for
the consideration of oral cholera vaccines as a part of the epidemic
response [15], the Ministry of Health and Public Hygiene
(MHPH) of Guinea supported by Me´decins Sans Frontie`res –
Operational Center Geneva (MSF-OCG), implemented a vacci-
nation campaign in the prefectures of Boffa and Fore´cariah. The
vaccine Shanchol (Shantha Biotechnics, India), prequalified by the
WHO, contains killed bacteria V. cholerae O1 and O139 and, given
in two doses 14 days apart, provides nearly 70% protection for at
least 2 years after vaccination [16]. A total of 7,531 cases including
138 deaths (case fatality ratio of 1.8%) were reported to the
MHPH of Guinea between the beginning of the epidemic and its
end, which was declared on 6 February 2013, after six consecutive
weeks without any new case notification [17].
Given that the RDT Crystal VC detects the LPS antigens of V.
cholerae O1 and O139 in feces, which are also contained in the oral
vaccine Shanchol, we hypothesized that the stools of vaccinated
individuals could become positive by the rapid test due to the
vaccine only, in the absence of viable bacteria. In a reactive
campaign during an outbreak, positive test results due to the
vaccine could interfere with the use of the tests in suspected
cholera cases. The aim of this study was to estimate the proportion
of positive results of the test Crystal VC in recipients of the cholera
vaccine Shanchol at different time points after vaccination and the
mean time to become negative (in those with an initial positive
result for O1 or O139) after vaccination.
Methods
Ethics statement
The study protocol was approved by the Ethical Review Board
(ERB) of Guinea and the MSF ERB. Written informed consent
was obtained from adults or from the guardians of participants less
than 18 years of age. Privacy and confidentiality in the data
collected from the participants were ensured both during and after
the conduct of the study.
Setting, population and study design
The study took place in Kabak (Fore´cariah Prefecture, Guinea)
during the second round of the mass vaccination campaign carried
out by the MHPH/MSF in June 2012. The study population
corresponded to the population targeted by the vaccination
campaign (all residents of Kabak aged one year and above).
Individuals were included if they were vaccinated and accepted to
participate. They were excluded if they had watery diarrhea on
inclusion (to exclude potential cholera cases) and/or a high
probability of not being present for all the follow-up visits. The
cohort of vaccinated participants meeting study criteria was
followed-up prospectively.
We estimated that 96 individuals were needed to achieve a
minimum precision of 10% around a proportion of 50% of
positive RDT, as there were no data on the prevalence of positive
tests in the vaccinated population. We increased the sample size to
106 to account for an expected 10% of loss to follow-up. A
systematic sampling method (one every 10 individual) was used in
every vaccination site.
Recruitment and follow-up procedures
Participants were recruited in 4 of the 31 vaccination sites,
selected arbitrarily, as vaccination sites were not thought to have
any influence on the study outcomes. Demographic information
was collected at inclusion through a face-to-face interview (mainly
in Soussou, the local language) and information on stool
production and basic clinical symptoms during follow-up visits
using an individual standardized case report form (CRF).
Participants were asked to collect stool in a pot provided by the
study team. Participants’ homes were visited daily to collect stool
specimens, complete a follow-up form and to provide them with a
new pot for the next stool. We transported the stools to the
laboratory and tested them with the RDT. Laboratory technicians
completed the information with the RDT results. Follow-up was
considered finalized when 2 consecutive negative RDT results
were obtained or after 7 days.
Field use of the rapid diagnostic test
The stool samples were tested with the RDT at Kabak Health
Center following the manufacturer’s instructions by a laboratory
technician trained to the use of the test. Crystal VC tests used were
manufactured in 2011 and 2012 by Span Diagnostics Ltd., India
(catalogue reference number 161C101-10). A small portion of
stool was mixed with a buffer and 200 mL (4 drops) of the mix was
placed in a test tube. The dipstick test was left in the tube for
20 minutes before reading. If only the control line appeared, the
Author Summary
The rapid diagnostic test (RDT) Crystal VC detects
lipopolysaccharide antigens from V. cholerae O1 and
O139 in stool samples, which are also present in the oral
cholera vaccine Shanchol. It is important to take into
consideration the possibility of a positive result to the RDT
due to vaccination and not to cholera in recently
vaccinated individuals. During a large mass cholera
vaccination campaign in Kabak (Guinea) in 2012, we
conducted a study to estimate the proportion of positive
results to the RDT in recipients of the oral cholera vaccine
at different time points after vaccination. The results of this
study show that ingestion of the cholera vaccine led to a
positive RDT, although almost exclusively to the O139
antigen, in the majority of vaccinated people. From the
fifth day after vaccination, only a small minority of
vaccinated individuals remained positive for the RDT and
none of the specimens tested the seventh day of follow-up
were positive. Our findings provide the first data on the
use of the RDT Crystal VC in vaccinated people. This test
should be used carefully during the first week after
reactive mass oral cholera vaccination campaigns in areas
where V. cholerae O139 is present.
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test was negative. If 2 or 3 lines appeared, the test was positive for
either V. cholerae O139, O1, or both. If the control line was absent,
the test was considered invalid and repeated once.
Laboratory control of the rapid diagnostic test
Ten by ten dilutions of the Shanchol vaccine were prepared
using the dilution buffer provided in the RDT kit. Undiluted and
diluted vaccine solutions up to a 109-fold dilution were tested with
the RDT following the manufacturer’s recommendations.
A bacterial suspension adjusted to an optical density at 600 nm
(OD600 nm) of 0.8 was prepared in the dilution buffer provided in
the RDT kit from an overnight culture of V. cholerae O1 and O139
strains. Such an OD value was previously estimated to correspond
to 26108 V. cholerae/mL by colony counting of 10-fold serial
dilutions spread on agar plates and incubated over night at 37uC.
This initial solution was used to prepare solutions at 26107 and
26106 bacteria/mL using the dilution buffer provided in the kit,
undiluted and diluted solutions were tested with the RDT
following the manufacturer’s recommendations.
Data analysis
Qualitative variables were described through their frequency
and percentages. Continuous variables were described through
their mean, median, standard deviation (SD) and percentiles (P25
and P75). We calculated the proportion of positive results for O1 or
O139 for each day of follow-up including in the numerator the
number of positive results and in the denominator the sum of the
total number of tests performed and the number of cases for whom
follow-up was stopped after obtaining two consecutive negative
results. Missing data (absent or no stool sample) were excluded
from this calculation. The 95% exact confidence intervals (95%CI)
of the proportion estimate were calculated. To estimate the mean
time to obtain a negative RDT result after vaccination (time to
become negative) we counted the number of days needed to obtain
a first negative result in the group of people who obtained
previously a positive result for O1 or O139 after vaccination.
Statistically significant differences by gender and age were assessed
with a linear regression model. A p value,0.05 was considered
significant.
Data were entered in an EpiData version 3.1 database
(EpiData, Odense, Denmark) and analyzed using Stata version
11 (StataCorp, College Station, Texas, USA).
Results
Recruitment and follow-up
A total of 108 individuals were recruited during 2 days in 4
vaccination sites. Two individuals were excluded from the analysis
(one was absent during all follow-up visits and for the other, follow-
up was stopped accidentally by the study team).
Follow-up of the remaining 106 participants is described in
Figure 1. Participants were followed for a median time of 5 days
(minimum of 2 and 7 as maximum). Almost half of them (49.1%)
were followed for 4 (23.6%) or 5 days (26.4%).
Participant’s characteristics, symptoms and delay in stool
collection and testing
Among the 106 participants, 79.2% (84) were females and the
median age was 25 years (P25-P75 = 2–80). The majority of
participants were older than 15 (84.8%) and the proportion of
children under five was 5.7%.
In total, 18 participants declared having diarrhea during follow-
up, and two reported vomiting. Other symptoms such as
constipation, stomachache or headache were declared by 37
participants.
The average delay was 3.9 hours (SD=4.4) between stool
production and collection and 6.6 hours (SD=5.9) between stool
collection and performance of the RDT (including collection and
transport of samples to the laboratory) by the laboratory
technicians. As a result, there was an average delay of 10.5 hours
(SD=6.6) between stool production and performance of the RDT.
Proportion of positive tests after vaccination
Of the 106 participants, 100 (94.3%) became positive with the
O139 line after vaccination and 6 never had a positive result. On
the first day of follow-up (day 1) 71.1% were positive. On day 3,
almost half of the tests remained positive (49.5%) and on day 5 and
6 this percentage decreased below 3% (Table 1).
Figure 1. Study participants, exclusions and follow-up results, Kabak, 2012.
doi:10.1371/journal.pntd.0002366.g001
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Only one participant became positive with the O1 line (together
with the O139 line) on the first day of monitoring, and both lines
became negative subsequently.
Time to become negative
Of the 100 participants with at least one positive result, five
could not be tested on day 7 as they were absent or did not
produce stools, although they had a positive result with their last
specimen collected (Figure 1). Among these 5 participants, 3 had
their last positive stool on day 3, 1 on day 4 and 1 on day 5. For
the remaining 95 cases with O139 positive tests, we calculated the
time to become negative after vaccination.
For all participants, the mean time to become negative after
vaccination was 3.8 days (SD=1.1) and the median time was 4
days (P25-P75 = 3–5). For males, the mean time to become negative
after vaccination was 4.3 days (SD=1.4) and 3.6 (SD=1) for
females (p = 0.03), with a median of 4 days for both males and
females. A linear regression model showed that a longer time to
become negative was associated to an older age (p = 0.002) and to
male sex (p = 0.012) (Table 2).
Laboratory testing of the rapid diagnostic test
The Crystal VC RDT gave positive results for both O1 and
O139 when the strip was inserted directly into the vaccine solution
prior to ingestion, and remained positive up to 104-fold dilutions of
the vaccine. At a 105-fold dilution, only the O139 line remained
positive and none of them were positive at higher dilutions
(Table 3).
The RDT gave a positive signal with the O1 test line at bacterial
concentration of 26108 and 26107, but was negative at 26106
bacteria/mL, while all dilutions of V. cholerae O139 culture tested
down to 26106 bacteria/mL were positive for the O139 line
(Table 3).
Discussion
To our knowledge, this is the first study showing that healthy
individuals vaccinated with the oral vaccine Shanchol become
positive with the cholera rapid test Crystal VC in the first days
following vaccination. The proportion of vaccinated individuals
Table 1. Rapid diagnostic test results in vaccinated participants by day of follow-up, Kabak, 2012.
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day7
A. Tests performed 97 97 90 76 46 23 6
a.1. Positive result (+) 69 80 47 20 2 1 0
a.2. Negative result (2) 28 17 43 56 44 22 6
B. Follow-up stopped after 2(2) 0 0 5 17 42 67 85
C. Absent 1 0 0 1 1 4 5
D. No sample available 8 9 11 12 17 12 10
Total1 106 106 106 106 106 106 106
Proportion2 of positives (%) 71.1 82.5 49.5 21.5 2.3 1.1 0.0
95%CI of the proportion 61.5–79.9 73.4–89.4 39.1–59.9 13.7–31.2 0.3–8.1 0.0–6.0 0.0–4.03
1The total is the sum of A+B+C+D.
2The proportion is the result of the formula (a.1/(A+B))*100.
397.5% Confidence Interval, one-sided.
doi:10.1371/journal.pntd.0002366.t001
Table 2. Linear regression model of time to become negative
by age and sex, Kabak, 2012.
Coefficient
95% Confidence
Interval p
Age1 0.020 (0.008–0.032) 0.002
Sex2 0.669 (0.153–1.186) 0.012
1The coefficient shows the increase in days in the time to become negative per
year of age.
2The coefficient shows the increase in days in the time to become negative for
males compared to females.
doi:10.1371/journal.pntd.0002366.t002
Table 3. Rapid diagnostic test results performed in vaccine
and bacterial suspension dilutions, Pasteur Institute, 2012.
Control
line
Line
T1 O139
Line
T2 O1
Vaccine dilutions
Tube 1 (10-fold dilution) +++ +++ +++
Tube 2 (102-fold dilution) +++ +++ +++
Tube 3 (103-fold dilution) +++ +++ ++
Tube 4 (104-fold dilution) +++ ++ +
Tube 5 (105-fold dilution) +++ + 2
Tube 6 (106-fold dilution) +++ 2 2
Tube 7 (107-fold dilution) +++ 2 2
Tube 8 (108-fold dilution) +++ 2 2
Tube 9 (109-fold dilution) +++ 2 2
O1 and O139 strains dilutions +++
O1 - Tube 1 (26108bacteria/mL) +++ 2 +++
O1 - Tube 2 (26107 bacteria/mL) +++ 2 ++
O1 - Tube 3 (26106 bacteria/mL) +++ 2 2
O139 - Tube 1 (26108 bacteria/mL) +++ +++ 2
O139 - Tube 2 (26107 bacteria/mL) +++ +++ 2
O139 - Tube 3 (26106 bacteria/mL) +++ ++ 2
Intensity of the positive line: (+) very weak positive; (++) weak positive; (+++)
positive.
Negative result: (2).
doi:10.1371/journal.pntd.0002366.t003
Cholera Rapid Test and Oral Cholera Vaccines
PLOS Neglected Tropical Diseases | www.plosntds.org 4 August 2013 | Volume 7 | Issue 8 | e2366
positive for the Crystal VC test after vaccination was high (94.3%)
for the O139 component of the test, but low with the O1
component. This proportion of O139-positive tests decreased
rapidly to half on the third day after vaccination and to one-fifth
on the fourth day of follow-up. The median duration required to
have a negative result for those cases presenting a previous positive
test was 4 days.
Almost all positive tests (except for one) were positive only for
O139 line, despite the fact that the Shanchol vaccines contains the
two strains V. cholerae O1 and O139, with a higher amount of O1
(1500 Elisa units of V. cholerae O1 LPS and 600 Elisa units of V.
cholerae O139 LPS for a dose of 1.5 mL) [18]. This could be due to
a higher sensitivity of the RDT for the O139, as suggested by the
results of sensitivity against bacterial cultures showing that the
O139 line was reactive with higher bacterial dilutions than the O1
line. Such results were already reported by Nato et al. [7] when
evaluating the initial version of the RDT, but are in contradiction
with those observed by Mukherjee et al. [13] with the first version
of the Crystal VC test, which was reactive at 106 bacteria/mL for
V. cholerae O1 and 107 bacterial/mL for V. cholerae O139. These
differences of analytical sensitivity between the different versions of
the RDT emphasize the need for a proper diagnostic performance
evaluation of each new version of the test.
Including pre-vaccination stool status of our study population as
well as unvaccinated participants could have provided useful
information on the magnitude of potential false positive reactions
due to factors unrelated to vaccination, i.e. non-specific reactions,
which could have been expected considering the reported
moderate specificity of the test [4,11–13], or positivity due to
asymptomatic carriers. The sharp increase and subsequent
decrease in the proportion of O139 positive tests after vaccination
are not in favour of such assumptions and suggest that the positive
results were due to the vaccine alone. Of the 75 tests done after
day 5, only three (4%) were positive for O139, and overall only
one test was positive for O1 which is lower than the number of
false positives that could be expected based on the test specificity.
However, it should be noted that this study was conducted in
people without cholera symptoms while the previous evaluations
were conducted in suspected cholera cases.
There are several limitations worth noting. First, women and
adults were overrepresented in our study sample. Although women
were more vaccinated than men were during the vaccination
campaign carried out in Kabak, the proportion of women in our
study (79.3%) was clearly higher than the vaccinated population
(59.5%) [19]. This is likely due to the fact that the majority of men
presented early at the vaccination site and were more likely to be
excluded given their potential absence for work during the follow-
up period. However, although there was a small difference in the
mean time to become negative between men and women (4.3 days
vs. 3.6), the median was the same for both sexes (4 days) thereby
not likely affecting the results presented here. The median age in
the study was 25 years compared to 15 for the vaccinated
population [19]. Considering that the time to become negative was
longer for the older participants, it is likely that we slightly
overestimated the time to become negative. Nonetheless, the
differences by age were small in magnitude (0.2 days per 10 years
of age) and they do not change the interpretation of the results
neither our recommendations regarding the use of the cholera
RDT in vaccinated areas. Second, we could not conclude on five
cases who had a positive result with their last specimen collected,
and for whom further samples could not be collected because they
were absent or unable to produce stool samples. When designing
the study, we decided to limit the follow-up period to 7 days, based
on the expected time for gastrointestinal transit of the killed
bacteria. Although extending the follow-up of participants until
they became negative for the rapid test would have been useful for
concluding on these 5 individuals, we consider that this limit was
reasonable in the absence of any other data. In addition, even if we
consider that these five people were still positive at day 7, the
percentage of positive tests would be still low (5.2%), lower than
the expected for non-cholera cases considering the specificity of
the test. Third, we did not perform culture to exclude participants
with possible cholera or asymptomatic carriage of V. cholerae.
Although initially planned in the protocol for participants with
diarrhea or with a positive RDT at the end of follow-up (day 7), no
culture was performed since symptoms were found unreliable and
none of the specimens tested on the seventh day of follow-up were
positive. Finally, specimens were tested on average ten hours after
stool production and without the possibility of storage at 4uC due
to the lack of electricity in Kabak. This delay seems reasonable
given the difficulties to collect the samples immediately after
production, although it is unclear the degree to which antigens
degrade during this period, which could potentially affect the
RDT results.
The results of the study confirm our hypothesis that the rapid
test Crystal VC can become positive in persons recently vaccinated
against cholera, although only with the O139 line, probably linked
to its higher analytical sensitivity. However, tests become negative
rapidly and five days after vaccination the proportion of positive
tests among vaccinated is less than 3%. As the current global
pandemic is almost exclusively caused by Vibrio cholerae O1, our
results suggest that the current Crystal VC kit can be used
normally as soon as 24 h after receiving Shanchol in a context of
V. cholerae O1 epidemic, and after a period of five days in areas
where V. cholerae O139 is present. Other cholera rapid diagnostic
tests based on the LPS detection are available in the market [20]
and could also become positive in recently vaccinated individuals.
Thus, an evaluation of other tests or future versions of the Crystal
VC test is recommended if they are to be used in the context of
oral cholera vaccination campaigns. Finally, we strongly recom-
mend that the diagnostic performances of the current modified
version of the Crystal VC test be evaluated with respect to the
different sensitivities of the O1 and O139 lines.
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